ContraFect (NASDAQ:CFRX) Shares Gap Up to $0.42

Share on StockTwits

ContraFect Corp (NASDAQ:CFRX) gapped up before the market opened on Tuesday . The stock had previously closed at $0.39, but opened at $0.42. ContraFect shares last traded at $0.50, with a volume of 2828383 shares.

Several equities research analysts have recently commented on CFRX shares. Chardan Capital restated a “buy” rating and set a $1.50 price target on shares of ContraFect in a research note on Wednesday, May 15th. Maxim Group started coverage on ContraFect in a research note on Tuesday. They set a “buy” rating for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. ContraFect has a consensus rating of “Buy” and an average price target of $1.50.

The stock has a market capitalization of $36.93 million, a PE ratio of -1.26 and a beta of -0.14. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.20.

ContraFect (NASDAQ:CFRX) last released its quarterly earnings data on Friday, May 10th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.26. As a group, analysts expect that ContraFect Corp will post -0.14 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in CFRX. White Pine Capital LLC raised its position in ContraFect by 207.9% in the first quarter. White Pine Capital LLC now owns 907,430 shares of the biotechnology company’s stock worth $361,000 after acquiring an additional 612,700 shares in the last quarter. Vanguard Group Inc. raised its position in ContraFect by 24.2% in the third quarter. Vanguard Group Inc. now owns 2,634,428 shares of the biotechnology company’s stock worth $5,454,000 after acquiring an additional 512,940 shares in the last quarter. Lombard Odier Asset Management USA Corp raised its position in ContraFect by 66.7% in the first quarter. Lombard Odier Asset Management USA Corp now owns 500,000 shares of the biotechnology company’s stock worth $199,000 after acquiring an additional 200,000 shares in the last quarter. Hartwell J M Limited Partnership raised its position in ContraFect by 150.0% in the first quarter. Hartwell J M Limited Partnership now owns 100,000 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 60,000 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in ContraFect by 106.0% in the first quarter. Wells Fargo & Company MN now owns 89,287 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 45,935 shares in the last quarter. Hedge funds and other institutional investors own 37.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/4370747/contrafect-nasdaqcfrx-shares-gap-up-to-0-42.html.

About ContraFect (NASDAQ:CFRX)

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Read More: Strangles

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

ContraFect  Shares Gap Up to $0.42
ContraFect Shares Gap Up to $0.42
Argentum   Trading 4.1% Lower  This Week
Argentum Trading 4.1% Lower This Week
Zacks: Brokerages Anticipate Green Plains Partners LP  Will Post Quarterly Sales of $21.27 Million
Zacks: Brokerages Anticipate Green Plains Partners LP Will Post Quarterly Sales of $21.27 Million
ALACERGOLD/IDR UNRESTR  Hits New 1-Year High at $4.52
ALACERGOLD/IDR UNRESTR Hits New 1-Year High at $4.52
CyberMusic Reaches 24-Hour Volume of $3,875.00
CyberMusic Reaches 24-Hour Volume of $3,875.00
Ergo  Price Hits $2.32 on Top Exchanges
Ergo Price Hits $2.32 on Top Exchanges


© 2006-2019 Ticker Report